OrthoPediatrics Corp Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
OrthoPediatrics Corp (KIDS) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$16.26 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-03-03
- OrthoPediatrics Corp income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$16.26M.
- OrthoPediatrics Corp income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$32.94M.
- OrthoPediatrics Corp income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was -$12.69M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2021-12-31 | -$16.26M 10-K · filed 2022-03-03 |
| 2020-12-31 | -$32.94M 10-K · filed 2022-03-03 |
| 2019-12-31 | -$12.69M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| CARLSMED, INC. (CARL) | United States | $0.405B |